Moreover, blockade of IL-6 signaling by the administration of an antibody that binds to the IL-6 receptor significantly reduces GVHD-associated mortality and, specifically, pathologic damage within the colon (28–30). The gene discussed is IL6; the disease is graft versus host disease.